16. Lehner LJ, Kleinsteuber A, Halleck F, Khadzhynov D, Schrezenmeier E, Duerr M, et al. Assessment of the Kidney Donor Profile Index in a European cohort. Nephrol-ogy, dialysis, transplantation : official publication of the European Dialysis and Trans-plant Association - European Renal Association. 2018.
17. Israni AK, Salkowski N, Gustafson S, Snyder JJ, Friedewald JJ, Formica RN, et al. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. Journal of the American Society of Nephrology : JASN. 2014;25(8):1842-8.
18. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231-6.
19. A Guide to Calculating the Kidney Donor Profile Index (KDPI). http://optn.trans-
plant.hrsa.gov/ContentDocuments/Guide_to_Calculating_Interpret-ing_KDPI.pdf.abgerufen am 29.1.2018.
20. Bae S, Massie AB, Luo X, Anjum S, Desai NM, Segev DL. Changes in Discard Rate After the Introduction of the Kidney Donor Profile Index (KDPI). American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016;16(7):2202-7.
21. Gandolfini I, Buzio C, Zanelli P, Palmisano A, Cremaschi E, Vaglio A, et al. The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pre-transplant donor biopsy assessment: distribution and association with graft outcomes.
American journal of transplantation : official journal of the American Society of Trans-plantation and the American Society of Transplant Surgeons. 2014;14(11):2515-25.
22. Gupta A, Chen G, Kaplan B. KDPI and donor selection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014;14(11):2444-5.
23. Tanriover B, Mohan S, Cohen DJ, Radhakrishnan J, Nickolas TL, Stone PW, et al. Kidneys at higher risk of discard: expanding the role of dual kidney transplantation.
American journal of transplantation : official journal of the American Society of Trans-plantation and the American Society of Transplant Surgeons. 2014;14(2):404-15.
24. Rehse G, Halleck F, Khadzhynov D, Lehner LJ, Kleinsteuber A, Staeck A, et al.
Validation of the Living Kidney Donor Profile Index in a European cohort and compari-son of long-term outcomes with US results. Nephrology, dialysis, transplantation : offi-cial publication of the European Dialysis and Transplant Association - European Renal Association. 2018.
25. Ojo AO, Morales JM, Gonzalez-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrology, dialysis, transplantation : official publication of the European Dialy-sis and Transplant Association - European Renal Association. 2013;28(1):213-20.
26. Cozzi E, Biancone L, Lopez-Fraga M, Nanni-Costa A. Long-term Outcome of Living Kidney Donation: Position Paper of the European Committee on Organ Trans-plantation, Council of Europe. Transplantation. 2016;100(2):270-1.
27. Araujo AM, Santos F, Guimaraes J, Nunes CS, Casal M. Living-donor Kidney Transplantation: Predictive Factors and Impact on Post-transplant Outcome. Trans-plantation proceedings. 2015;47(4):938-41.
28. Fuggle SV, Allen JE, Johnson RJ, Collett D, Mason PD, Dudley C, et al. Factors affecting graft and patient survival after live donor kidney transplantation in the UK.
Transplantation. 2010;89(6):694-701.
29. Noppakun K, Cosio FG, Dean PG, Taler SJ, Wauters R, Grande JP. Living do-nor age and kidney transplant outcomes. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Trans-plant Surgeons. 2011;11(6):1279-86.
30. Gore JL, Danovitch GM, Litwin MS, Pham PT, Singer JS. Disparities in the utili-zation of live donor renal transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Trans-plant Surgeons. 2009;9(5):1124-33.
31. Massie AB, Leanza J, Fahmy LM, Chow EK, Desai NM, Luo X, et al. A Risk In-dex for Living Donor Kidney Transplantation. American journal of transplantation : offi-cial journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016;16(7):2077-84.
32. Lee AP, Abramowicz D. Is the Kidney Donor Risk Index a step forward in the assessment of deceased donor kidney quality? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Re-nal Association. 2015;30(8):1285-90.
33. Lim WH, Wong G, Heidt S, Claas FHJ. Novel aspects of epitope matching and practical application in kidney transplantation. Kidney international. 2017.
34. Lachmann N, Terasaki PI, Schonemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Clinical transplants. 2006:171-99.
35. Susal C, Opelz G. Current role of human leukocyte antigen matching in kidney transplantation. Current opinion in organ transplantation. 2013;18(4):438-44.
36. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al.
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. American journal of transplantation : official journal of the Amer-ican Society of Transplantation and the AmerAmer-ican Society of Transplant Surgeons.
2012;12(5):1157-67.
37. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Reviews in immunogenetics.
1999;1(3):334-42.
38. Takemoto S, Port FK, Claas FH, Duquesnoy RJ. HLA matching for kidney transplantation. Human immunology. 2004;65(12):1489-505.
39. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, et al. De novo DQ donor-specific antibodies are associated with a significant risk of an-tibody-mediated rejection and transplant glomerulopathy. Transplantation.
2012;94(2):172-7.
40. Hormann M, Dieplinger G, Rebellato LM, Briley KP, Bolin P, Morgan C, et al. In-cidence and impact of anti-HLA-DP antibodies in renal transplantation. Clinical trans-plantation. 2016;30(9):1108-14.
41. Lim WH, Chapman JR, Coates PT, Lewis JR, Russ GR, Watson N, et al. HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. Clinical journal of the American Society of Nephrology : CJASN. 2016;11(5):875-83.
42. Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015;15(5):1148-54.
43. Lachmann N, Niemann M, Reinke P, Budde K, Schmidt D, Halleck F, et al. Do-nor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes In-dependently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Follow-ing Renal Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Sur-geons. 2017;17(12):3076-86.
44. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue antigens. 2011;77(6):525-34.
45. Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCII-pan-3.0, a common pan-specific MHC class II prediction method including all three hu-man MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics.
2013;65(10):711-24.
46. Conlon TM, Saeb-Parsy K, Cole JL, Motallebzadeh R, Qureshi MS, Rehakova S, et al. Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. Journal of immunology (Baltimore, Md : 1950).
2012;188(6):2643-52.
47. Otten HG, Calis JJ, Kesmir C, van Zuilen AD, Spierings E. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo develop-ment of donor-specific HLA IgG antibodies after kidney transplantation. Human immu-nology. 2013;74(3):290-6.
48. de Fijter JW. An old virtue to improve senior programs. Transplant international : official journal of the European Society for Organ Transplantation. 2009;22(3):259-68.
49. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. Journal of the American Society of Nephrology : JASN. 2001;12(3):589-97.
50. Halleck F, Khadzhynov D, Liefeldt L, Schrezenmeier E, Lehner L, Duerr M, et al. Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching? Nephrology, dialysis, transplantation : official publication of the European Di-alysis and Transplant Association - European Renal Association. 2016;31(12):2143-9.
51. Langer RM, Cohen B, Rahmel A. History of eurotransplant. Transplantation pro-ceedings. 2012;44(7):2130-1.
52. Lehner LJ, Staeck O, Halleck F, Liefeldt L, Bamoulid J, Budde K. Need for opti-mized immunosuppression in elderly kidney transplant recipients. Transplantation re-views (Orlando, Fla). 2015;29(4):237-9.
53. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa LY, et al. In-creased immunosuppressive vulnerability in elderly renal transplant recipients. Trans-plantation. 2000;69(5):885-9.
54. Dreyer GJ, Hemke AC, Reinders ME, de Fijter JW. Transplanting the elderly:
Balancing aging with histocompatibility. Transplantation reviews (Orlando, Fla).
2015;29(4):205-11.
55. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic acids research.
2015;43(Database issue):D423-31.
56. Doxiadis, II, de Fijter JW, Mallat MJ, Haasnoot GW, Ringers J, Persijn GG, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation. 2007;83(9):1207-13.
57. Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RW. Im-portance of minimizing HLA-DR mismatch and cold preservation time in cadaveric re-nal transplantation. Transplantation. 1996;61(5):709-14.
58. Fisher RA. Cytomegalovirus infection and disease in the new era of immuno-suppression following solid organ transplantation. Transplant infectious disease : an of-ficial journal of the Transplantation Society. 2009;11(3):195-202.
59. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician's update. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011;58(1):118-26.
60. Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.
Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative
Re-cipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Serocon-version and Prevents Cytomegalovirus Disease. Transplantation proceedings.
2017;49(10):2280-4.
61. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis.
American journal of transplantation : official journal of the American Society of Trans-plantation and the American Society of Transplant Surgeons. 2011;11(9):1936-42.
62. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Ef-ficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy.
2004;24(10):1323-30.
63. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplanta-tion. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. The New England journal of medicine. 1999;340(19):1462-70.
64. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al.
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333-60.
65. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al.
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Sur-geons. 2010;10(5):1228-37.
66. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clinical infectious diseases : an official publication of the In-fectious Diseases Society of America. 2011;52(3):313-21.
67. Konigshausen E, Sellin L. Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. BioMed research international. 2016;2016:3765608.
68. Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, et al. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Ex-change and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte beta3-integrin Activation. Transplantation.
2015;99(12):2593-7.
69. Staeck O, Halleck F, Budde K, Khadzhynov D. Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis.
Transplantation proceedings. 2017;49(10):2256-9.
70. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomeruloscle-rosis in nephrotic adults: presentation, prognosis, and response to therapy of the histo-logic variants. Journal of the American Society of Nephrology : JASN. 2004;15(8):2169-77.
71. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2010;25(1):25-31.
72. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allo-graft loss from recurrent glomerulonephritis. The New England journal of medicine.
2002;347(2):103-9.
73. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclero-sis in renal allograft: an in-depth review. Pediatric transplantation. 2010;14(3):314-25.
74. Messina M, Gallo E, Mella A, Pagani F, Biancone L. Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World journal of transplan-tation. 2016;6(1):54-68.
75. Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, et al.
OPTN/SRTR 2015 Annual Data Report: Kidney. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017;17 Suppl 1:21-116.
76. Jay CL, Washburn K, Dean PG, Helmick RA, Pugh JA, Stegall MD. Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys.
Transplantation. 2017;101(4):867-72.
77. Massie AB, Luo X, Chow EK, Alejo JL, Desai NM, Segev DL. Survival benefit of primary deceased donor transplantation with high-KDPI kidneys. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014;14(10):2310-6.
78. Eurotransplant International Foundation. Annual Report 2014. www.eurotrans-plant.org. (abgerufen am 29.1.2018).
79. Vinkers MT, Smits JM, Tieken IC, de Boer J, Ysebaert D, Rahmel AO. Kidney donation and transplantation in Eurotransplant 2006-2007: minimizing discard rates by using a rescue allocation policy. Progress in transplantation (Aliso Viejo, Calif).
2009;19(4):365-70.
80. Wahba R, Teschner S, Stippel DL. Results of kidney transplantation after res-cue allocation. Transplant international : official journal of the European Society for Or-gan Transplantation. 2011;24(6):e46-7.
81. Wahba R, Suwelack B, Arns W, Cakiroglu F, Eisenberger U, Feldkamp T, et al.
Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs. Transplant international : official journal of the European Society for Organ Transplantation. 2017;30(12):1226-33.
82. VanWagner LB, Skaro AI. Program-specific reports: implications and impact on program behavior. Current opinion in organ transplantation. 2013;18(2):210-5.
83. White SL, Zinsser DM, Paul M, Levine GN, Shearon T, Ashby VB, et al. Patient selection and volume in the era surrounding implementation of Medicare conditions of participation for transplant programs. Health services research. 2015;50(2):330-50.
84. Gaston RS. IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLAN-TATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES. Transactions of the American Clinical and Climatological Associa-tion. 2016;127:350-61.
85. Gill JS, Tonelli M. Penny wise, pound foolish? Coverage limits on immunosup-pression after kidney transplantation. The New England journal of medicine.
2012;366(7):586-9.
86. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, et al. OPTN/SRTR 2013 Annual Data Report: kidney. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015;15 Suppl 2:1-34.
87. Lloveras J, Arcos E, Comas J, Crespo M, Pascual J. A paired survival analysis comparing hemodialysis and kidney transplantation from deceased elderly donors older than 65 years. Transplantation. 2015;99(5):991-6.
88. Rose C, Schaeffner E, Frei U, Gill J, Gill JS. A Lifetime of Allograft Function with Kidneys from Older Donors. Journal of the American Society of Nephrology : JASN.
2015;26(10):2483-93.
89. Tullius SG, Milford E. Kidney allocation and the aging immune response. The New England journal of medicine. 2011;364(14):1369-70.
90. Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged.
Immunology today. 2000;21(10):515-21.
91. McKay D, Jameson J. Kidney transplantation and the ageing immune system.
Nature reviews Nephrology. 2012;8(12):700-8.
92. de Fijter JW, Mallat MJ, Doxiadis, II, Ringers J, Rosendaal FR, Claas FH, et al.
Increased immunogenicity and cause of graft loss of old donor kidneys. Journal of the American Society of Nephrology : JASN. 2001;12(7):1538-46.
93. Oberhuber R, Ge X, Tullius SG. Donor age-specific injury and immune
re-sponses. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(1):38-42.
94. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Annals of surgery. 2010;252(4):662-74.
95. San-Juan R, Navarro D, Garcia-Reyne A, Montejo M, Munoz P, Carratala J, et al. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipi-ents in the development of CMV-specific cellular immunity and occurrence of late CMV disease. The Journal of infection. 2015;71(5):561-70.
96. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, et al.
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427-31.
97. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, Martin-Pena A, Sanchez B, Martin-Gandul C, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation. 2011;91(8):927-33.
98. Couser W. Recurrent glomerulonephritis in the renal allograft: an update of se-lected areas. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2005;3(1):283-8.
99. Cameron JS. Focal segmental glomerulosclerosis in adults. Nephrol Dial Trans-plant 2003;18(Suppl. 6):vi45e51.
100. Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, et al. In-tensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9(5):1081-6.
Danksagung
An erster Stelle möchte ich meiner Familie für ihre uneingeschränkte liebevolle Unterstützung danken.
Mein besonderer Dank gilt meinen Freunden und Kollegen der Arbeitsgruppe „Klinische Nephrologie und Transplantationsforschung“ für die hervorragende Zusammenarbeit:
Herrn Dr. Fabian Halleck, Herrn Dr. Dmytro Khadzhynov, Herrn Danilo Schmidt, Herrn Dr. Lukas Lehner und Herrn Dr. Michael Dürr.
Frau Dr. Katharina Kast danke ich sehr für die Unterstützung bei der Habilitationsschrift.
Zudem möchte ich mich bei meinem wissenschaftlichen Mentor Herrn Prof. Dr. Klemens Budde für die herausragende Unterstützung und Förderung meiner wissenschaftlichen Tätigkeit bedanken.
Für die gute Zusammenarbeit und kollegiale Unterstützung danke ich zudem Herrn Univ.-Prof. Dr. Kai-Uwe Eckardt und allen Kollegen der Medizinischen Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin.